Wellington Management Group
BBIO icon

Wellington Management Group’s BridgeBio Pharma BBIO Stock Holding History

Wellington Management Group’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$395M Buy
5,308,924
+2,824,971
+114% +$198M 0.07% 257
2026
Q1 		$184M Buy
2,483,953
+135,222
+6% +$9.8M 0.03% 399
2025
Q4 		$180M Buy
2,348,731
+1,329,537
+130% +$87.3M 0.03% 410
2025
Q3 		$52.9M Buy
1,019,194
+962,525
+1,699% +$46.9M 0.01% 713
2025
Q2 		$2.45M Sell
56,669
-3,342
-6% -$122K ﹤0.01% 1530
2025
Q1 		$2.07M Sell
60,011
-4,796
-7% -$162K ﹤0.01% 1551
2024
Q4 		$1.78M Sell
64,807
-4,779
-7% -$124K ﹤0.01% 1595
2024
Q3 		$1.77M Sell
69,586
-1,400,524
-95% -$36.8M ﹤0.01% 1573
2024
Q2 		$37.2M Sell
1,470,110
-71,775
-5% -$1.96M 0.01% 775
2024
Q1 		$47.7M Buy
1,541,885
+46,771
+3% +$1.59M 0.01% 716
2023
Q4 		$60.4M Buy
1,495,114
+75,564
+5% +$2.27M 0.01% 667
2023
Q3 		$37.4M Buy
+1,419,550
New +$40.3M 0.01% 773

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group's BBIO Position: Q2 2026 in Review

Wellington Management Group increased its BridgeBio Pharma (BBIO) stake by 114% in Q2 2026, buying an estimated $198M and bringing the position to 5,308,924 shares worth $395M. The position accounts for 0.07% of the portfolio, ranked #257.

Wellington Management Group first reported a position in BBIO in Q3 2023 and has held it in 12 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Wellington Management Group held 5,308,924 shares of BridgeBio Pharma worth $395M as of Q2 2026.
  • Wellington Management Group bought 2,824,971 BridgeBio Pharma shares in Q2 2026, an estimated $198M.
  • BridgeBio Pharma made up 0.07% of Wellington Management Group's portfolio in Q2 2026, its #257 holding.
  • Wellington Management Group first reported a position in BridgeBio Pharma in Q3 2023 and has held it in 12 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.